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SUMMARY 
 
Background 
Low-income and middle-income countries (LMICs) are under-represented in reports on the burden of 
antimicrobial resistance. We aimed to quantify the clinical effect of carbapenem resistance on mortality 
and length of hospital stay among inpatients in LMICs with a bloodstream infection due to 
Enterobacteriaceae. 
 
Methods 
The PANORAMA study was a multinational prospective cohort study at tertiary hospitals in Bangladesh, 
Colombia, Egypt, Ghana, India, Lebanon, Nepal, Nigeria, Pakistan, and Vietnam, recruiting consecutively 
diagnosed patients with carbapenem-susceptible Enterobacteriaceae (CSE) and carbapenem-resistant 
Entero-bacteriaceae (CRE) bloodstream infections. We excluded patients who had previously been 
enrolled in the study and those not treated with curative intent at the time of bloodstream infection 
onset. There were no age restrictions. Central laboratories in India and the UK did confirmatory testing 
and molecular characterisation, including strain typing. We applied proportional subdistribution hazard 
models with inverse probability weighting to estimate the effect of carbapenem resistance on probability 
of discharge alive and in-hospital death, and multistate modelling for excess length of stay in hospital. All 
patients were included in the analysis. 
 
Findings 
Between Aug 1, 2014, and June 30, 2015, we recruited 297 patients from 16 sites in ten countries: 174 
with CSE bloodstream infection and 123 with CRE bloodstream infection. Median age was 46 years (IQR 
15–61). Crude mortality was 20% (35 of 174 patients) for patients with CSE bloodstream infection and 
35% (43 of 123 patients) for patients with CRE bloodstream infection. Carbapenem resistance was 
associated with an increased length of hospital stay (3·7 days, 95% CI 0·3–6·9), increased probability of in-
hospital mortality (adjusted subdistribution hazard ratio 1·75, 95% CI 1·04–2·94), and decreased 
probability of discharge alive (0·61, 0·45–0·83). Multilocus sequence typing showed various clades, with 
marginal overlap between strains in the CRE and CSE clades. 
 
Interpretation 
Carbapenem resistance is associated with increased length of hospital stay and mortality in patients with 
bloodstream infections in LMICs. These data will inform global estimates of the burden of antimicrobial 
resistance and reinforce the need for better strategies to prevent, diagnose, and treat CRE infections in 
LMICs. 
  
 INTRODUCTION 
Antimicrobial resistance (AMR) represents a substantial global health and economic threat, with 
resistance to so-called last-line antibiotics, such as carbapenems, of most concern.1, 2 An accurate 
estimate of the burden of AMR is needed to inform decisions about allocation of resources towards 
strategies such as infection control measures, antimicrobial stewardship, and development of new 
antimicrobials.3, 4 To date, only a few small studies have assessed the effect of carbapenem resistance on 
health outcomes, with most studies done in high-income settings.5, 6, 7, 8, 9, 10 Yet, it is likely that the burden 
is greatest in low-income and middle-income countries (LMICs).11 A 2011 meta-analysis of health-care-
associated infections in LMICs reported an almost complete absence of data regarding the effect of 
AMR,12 and WHO has identified a knowledge gap on the burden of AMR in this setting.2 
We aimed to describe the clinical features, outcomes, and molecular epidemiology of bloodstream 
infections caused by carbapenem-resistant Enterobacteriaceae (CRE) compared with carbapenem-
susceptible Enterobacteriaceae (CSE) in LMICs. Our primary objective was to quantify the effect of 
carbapenem resistance on in-hospital mortality and length of hospital stay among inpatients diagnosed 
with a bloodstream infection due to a member of the Enterobacteriaceae family in LMICs. 
 
METHODS 
 
Study design and participants 
We did a multinational prospective cohort study, the PANORAMA study. We established the PANORAMA 
network of local investigators from hospitals that met the following criteria: location in a country with a 
low-income or middle-income economy (at the time of patient recruitment),13 tertiary-level hospital 
according to WHO definition,14 and microbiology laboratory able to detect CRE.15 Patients were eligible if 
diagnosed with a bloodstream infection caused by a member of the Enterobacteriaceae family. We 
excluded patients who had previously been enrolled in the study and those not treated with curative 
intent at the time of bloodstream infection onset. Patients were recruited from hospitals linked to the 
local investigators. The exposure of interest was carbapenem resistance. We used an apportionment ratio 
of 1:1 to improve study precision.16 Local investigators enrolled consecutive eligible patients during a 6-
month study period up to an initial maximum of five patients with CSE bloodstream infections and five 
patients with CRE bloodstream infections (established by the local laboratory in each hospital). After 
recruiting the initial ten patients, centres were invited to include ten more patients (five CRE and five CSE) 
in an ongoing stepwise manner for a maximum of 6 months. Patients were followed-up until discharge or 
in-hospital death. Study data were collected and managed using REDCap electronic data capture tools 
hosted at the University of Melbourne, VIC, Australia.17 This study was approved by the human research 
ethics committee at each institution. In some cases, consent was obtained. More frequently, the need for 
consent was waived according to local human research ethics guidance. 
 
Outcomes 
The primary outcomes were in-hospital mortality and length of hospital stay. As in-hospital mortality and 
discharge alive are competing outcomes, we modelled the effect of carbapenem resistance on both.18 
 
Procedures 
Between Aug 1, 2014, and June 30, 2015, the local investigators collected the following patient-level 
covariates: age, sex, referral source (admission from long-term care facility, nursing home, or transfer 
from another hospital), severity of underlying illness (measured using the Charlson comorbidity index19), 
Pitt bacteraemia score20 at bloodstream infection onset, and intensive care unit admission or surgical 
procedure before the bloodstream infection. Sanitation was categorised by household latrine facilities (ie, 
open defecation), and education used as a surrogate for socioeconomic status. We collected the 
following information about bloodstream infections: onset date (first positive culture), 
Enterobacteriaceae species, polymicrobial infection, source of infection (ie, primary, central-line 
associated, or secondary bloodstream infection), and epidemiological attribution (ie, hospital acquired, 
community acquired, or health-care associated).21 Antibiotic treatment was recorded. Agents used from 
day 0 (onset date) to day 2 of infection were defined as initial treatment. Persistent bloodstream 
infection was defined as a positive follow-up blood culture containing the same Enterobacteriaceae after 
more than 48 h of active antimicrobial treatment, or in the case of a catheter-associated bloodstream 
infection, a positive blood-culture result more than 3 days after removing the catheter. Recurrent 
bloodstream infection was defined as bacteraemia due to the same microbiologically documented 
Enterobacteriaceae (ie, species and antimicrobial susceptibility pattern), developing after the 
discontinuation of treatment. Follow-up blood cultures were taken at the discretion of the treating 
clinicians. 
All blood culture isolates were processed in the clinical microbiology laboratory of each participating 
hospital for identification and antibiotic susceptibility testing, using standard microbiology methods. 
Strains were screened for carbapenem non-susceptibility according to recommendations of the 
International Working Group.15 All laboratories participated in an established external quality assurance 
programme. When possible, bacterial strains were sent to one of two central study laboratories (Cardiff, 
UK, and New Delhi, India) for confirmatory testing and molecular characterisation. 
Species identification of bacterial isolates was confirmed by matrix-assisted laser desorption/ionisation 
time-of-flight mass spectrometry (MALDI-TOF; Bruker Daltonik GmbH, Coventry, UK), according to 
manufacturer's instructions, and the acquired mass spectra were compared with mass spectra in the 
Bruker database using MALDI Biotyper 3.1 software. Antibiotic resistance profiles against different 
antibiotics were established by disc diffusion, and minimum inhibitory concentrations of ertapenem, 
meropenem, imipenem, and colistin were established by agar dilution.22 Tests and interpretation were 
done according to the European Committee on Antimicrobial Susceptibility Testing guidelines version 7.1 
(2017), and Escherichia coli ATCC25922 was used as the control. 
Bacterial isolates were screened for the presence of blaNDM, blaKPC, blaoxa-48-like, and blaVIM by PCR, and for 
the presence of blaIMP-1, blaIMP-2, and blaIMP-3 by multiplex and individual PCR; a subset was confirmed by 
sequencing. See the appendix for primer sequences, target genes, and PCR conditions. 
Multilocus sequence typing (MLST) was done following published protocols for (1) E coli and (2) Klebsiella 
pneumoniae. eBURST analysis was done to assess relationships between the different isolates on the 
basis of their sequence types (ST), and associated epidemiological data using PHYLOViZ. 
Statistical analysis 
The sample size estimate was based on an expected in-hospital mortality of 40% among exposed (CRE) 
patients and 20% among non-exposed (CSE) patients.6 GiveŶ aŶ α ǀalue of 0·05 aŶd poǁer of 80%, ǁe 
required 91 patients in each group to test the hypothesis that mortality is higher among exposed patients 
than among non-exposed patients. We assumed an institution-level intra-cluster correlation of 0·01 and a 
sample size of ten from each institution; therefore, we needed an actual sample size of 100 patients in 
each group to reach an effective sample size of 91. 
The effect of carbapenem resistance on the probability of mortality and discharge alive was estimated 
using proportional subdistribution hazards models (Fine and Gray models23), with time from infection as 
the timescale (time 0 is infection, with infection therefore included as a time-fixed covariate). Hospital 
stays were censored at 90 days. For both outcomes (mortality and discharge alive), two models were 
fitted. The base model adjusted only for time from admission to infection. We applied inverse probability 
weighting to this model to account for confounding.24 We computed a propensity score for each patient, 
representing their probability of being infected with a carbapenem-resistant strain, using boosted 
regression trees that included time from admission to infection, age, sex, Charlson comorbidity index, 
location before admission, Pitt bacteraemia score, bacterial organism, education, and sanitation as 
predictors.25 We then used Cox proportional subdistribution hazards models weighted by 1 divided by the 
propensity score for patients with CRE blood-stream infection and 1 divided by (1 minus propensity score) 
for patients with CSE bloodstream infection. Time from admission to infection was included as an 
independent variable for doubly robust estimation. To account for missing values, we imputed 50 
datasets using multiple imputation by chained equations (mice package), did the analysis described above 
with each dataset, and summarised results using Rubin's rule (appendix).26, 27, 28 
We used multistate modelling to estimate excess length of hospital stay associated with carbapenem 
resistance.29 We considered time from admission as the timescale. All patients entered the model at the 
time of infection in one of two states: CSE bloodstream infection or CRE bloodstream infection. Left 
truncation was taken into account by the estimators.30 Length of hospital stay is determined by moving 
into a final (ie, absorbing) state representing the day of discharge or in-hospital death. The excess length 
of hospital stay was based on non-parametric estimators of the transition probabilities associated with 
the multistate model (appendix).30 SEs and CIs were derived by bootstrap re-sampling runs. 
We did several sensitivity analyses. First, to evaluate the effect of timescale and to supplement the Fine 
and Gray models, we used Cox proportional hazards models to estimate the effect of carbapenem 
resistance on instantaneous risk of mortality, discharge alive, and a combined endpoint (all-cause end-of-
stay) using two timescales: time from admission and time from infection. Second, to address the 
possibility of misclassification bias, in addition to the primary analysis including all recruited patients (ie, 
complete cohort) all analyses described were repeated on the subset of patients whose bloodstream 
infection strain was transported to one of two central laboratories for confirmatory testing (ie, confirmed 
cohort). The analysis of the complete cohort, which could be considered an intention-to-treat analysis, is 
presented in the main text of this paper, whereas the results for the confirmed cohort and other 
statistical sensitivity analyses are presented in the appendix. Statistical analyses were done using R, 
version 3.3.2, including the survival, etm, mvna, twang, and mice packages. 
RESULTS 
16 hospitals agreed to participate in the study (appendix), comprising ten public and six private facilities, 
with a median of 400 acute care beds (IQR 270–1100). Hospitals were located in two countries with low-
income economies (Bangladesh and Nepal), six with lower-middle-income economies (Egypt, Ghana, 
India, Nigeria, Pakistan, and Vietnam), and two with upper-middle-income economies (Colombia and 
Lebanon). 14 (88%) of 16 hospitals had specialist units for neonates, 12 (75%) for obstetrics, ten (63%) for 
burns, nine (56%) for solid-organ transplantation, and six (38%) for bone-marrow transplantation. 
We recruited 297 patients between Aug 1, 2014, and June 30, 2015: 174 with CSE bloodstream infection 
and 123 with CRE bloodstream infection (figure 1). 297 patients were included in the complete cohort (ie, 
primary analysis). There were no dropouts. Missing data are described for each variable in table 1. 
Median age of all patients was 46 years (IQR 15–61); 182 (61%) participants were male and 115 (39%) 
were female (table 1). Open defecation at home was reported by 20 (8%) of 256 patients. Median age-
adjusted Charlson comorbidity index was 2·0 (IQR 0·0–5·0), and median Pitt bacteraemia score was 2·0 
(IQR 0·5–4·0) 
In-hospital mortality occurred in 35 (20%) of 174 patients with CSE bloodstream infection and in 43 (35%) 
of 123 patients with CRE bloodstream infection. Carbapenem resistance was associated with increased 
probability of in-hospital mortality and decreased probability of discharge alive in both the base and 
inverse probability weighted models (table 2). From the multistate model, carbapenem resistance was 
associated with 3·7 days (95% CI 0·3–6·9) excess length of stay in hospital. The results of the confirmed 
cohort and sensitivity analyses are consistent with those of the primary analysis in the complete cohort 
(appendix). From the isolates sent for confirmatory testing, positive predictive values for local laboratory 
designation of carbapenem resistance were 87% (84 of 97) and negative predictive values for local 
laboratory designation of carbapenem resistance were 96% (106 of 110). 
Exposure to health care before bloodstream infection onset was more frequent among patients with CRE 
bloodstream infection than those with CSE bloodstream infection. The median length of stay in hospital 
before bloodstream infection onset was 1 day (IQR 0–5) for patients with CSE bloodstream infection and 
4 days (0–14) for patients with CRE bloodstream infection (figure 2). Furthermore, more patients with 
CRE bloodstream infection had been exposed to antibiotics, intensive care, and surgery within the 30 
days before bloodstream infection onset than had the patients with CSE bloodstream infection (table 1) 
Antibiotic treatment is summarised in the appendix. Among 110 patients with CRE bloodstream infection, 
36 (33%) were prescribed a polymyxin as part of initial treatment. The antibiotic classes most frequently 
prescribed to patients with CRE bloodstream infection from day 3 onwards were carbapenems (55 [59%] 
of 93) and polymyxins (48 [52%] of 93), with 35 (38%) of 93 patients in this group receiving an antibiotic 
from both of these classes. Carbapenems were the most commonly used antibiotic class for CSE 
bloodstream infection, with 65 (39%) of 165 patients prescribed an agent from this class during the first 3 
days of infection (ie, initial treatment period) and 63 (47%) of 135 patients prescribed an agent from this 
class on subsequent days. 
Although the incidence of septic shock among patients with CSE bloodstream infection (46 [26%] of 174 
patients) and CRE bloodstream infection (33 [27%] of 123 patients) was similar, persistent bacteraemia 
was more frequently detected among patients with CRE bloodstream infection (21 [17%] of 123 patients) 
than CSE bloodstream infection (14 [8%] of 174 patients). Recurrent bacteraemia was also more 
frequently detected among patients with CRE bloodstream infection (eight [7%] of 123 patients) than CSE 
bloodstream infection (five [3%] of 174 patients). 
Antibiotic susceptibility against 14 distinct antibiotics was established for 101 K pneumoniae isolates, 65 E 
coli isolates, and 25 other Enterobacteriacae isolates (appendix). The antibiotic to which carbapenem-
resistant isolates were most frequently susceptible was colistin: 36 (83%) of 41 K pneumoniae isolates, all 
15 E coli isolates, and six (75%) of eight isolates of other Enterobacteriaceae. All CRE isolates were non-
susceptible to cephalosporins and aztreonam. Resistance to non-carbapenem antibiotics was also 
widespread among CSE, particularly K pneumoniae. All carbapenem-susceptible K pneumoniae, E coli, and 
other Enterobacteriaceae were susceptible to colistin, and amikacin (21 [57%] of 37) and tigecycline (18 
[53%] of 34]) were active against more than half of the carbapenem-susceptible K pneumoniae isolates. 
In total, 109 K pneumoniae and 66 E coli isolates were subjected to MLST. We identified 48 K pneumoniae 
STs. The most common were ST14 (n=15), a non-virulent clone associated with capsular serotype K2, and 
ST231 (n=14). 14 isolates belonged to clonal complex 258, including ST258, ST11, ST340, and ST2516. 35 
STs were uniquely represented by one isolate. Additionally, five new allelic profiles (figure 3) were 
identified and have been added to the K pneumoniae MLST database at Institut Pasteur (Paris, France). 
Among the E coli isolates, 34 STs were identified. The most common was ST131 (n=nine), with 20 STs 
represented by one isolate. eBURST diagrams based on the STs obtained for K pneumoniae and E coli 
isolates are shown by carbapenem susceptibility in figure 3 and by geographical region in the appendix. 
Among the 208 available isolates, blaNDM was the most commonly identified carbapenemase-encoding 
gene; it was present in 35 carbapenem-resistant K pneumoniae isolates (21 from south Asia, ten from 
Africa, and four from west Asia), ten carbapenem-resistant E coli isolates (seven from south Asia, two 
from Africa, and one from west Asia), two other carbapenem-resistant Enterobacteriaceae, and one 
carbapenem-susceptible Klebsiella oxytoca (from Pakistan). blaOXA-48-like genes were identified in 34 
carbapenem-resistant K pneumoniae isolates (29 from south Asia, four from Africa, and one from west 
Asia) and one carbapenem-susceptible K pneumoniae isolate (Africa). 11 carbapenem-resistant E coli 
isolates carried blaOXA-48-like genes (nine from south Asia and two from west Asia). blaKPC was detected in 
eight carbapenem-resistant K pneumoniae isolates (seven from South America and one from south Asia) 
and one carbapenem-susceptible K pneumoniae isolate from South America. blaKPC was also found in six 
carbapenem-resistant E coli isolates from south Asia and five carbapenem-resistant Enterobacter cloacae 
isolates. blaVIM genes were detected in three carbapenem-resistant K pneumoniae isolates from Egypt. No 
blaIMP genes were detected. Coexistence of two or more carbapenemase genes was identified in 22 
isolates. Carbapenemase-encoding genes were not found in one carbapenem-resistant E coli isolate 
(Ghana), 11 carbapenem-resistant K pneumoniae isolates (six from Ghana, three from India, and two from 
Egypt), and one K oxytoca isolate from Ghana. 
DISCUSSION 
These data show that in LMICs, patients with bloodstream infection caused by CRE have increased risk of 
death and length of stay in hospital compared with patients with bloodstream infection caused by CSE. 
Although this finding is not unexpected, data for the burden of AMR in LMICs are scarce, despite long-
standing recognition of this knowledge gap.31, 32 Such information is essential to justify the allocation of 
the resources required to strengthen laboratory, infection control, and antimicrobial stewardship 
capacity, and other strategies to address AMR in LMICs.33, 34 
Estimates of the global clinical burden of AMR need to include data from LMICs rather than being 
extrapolated from high-income countries for three reasons. First, there is an inverse relationship between 
national income and prevalence of drug-resistant infections.35 Potential reasons for this association 
include high population density, poor sanitation, contaminated water, environmental reservoirs, 
suboptimal implementation of infection control and antimicrobial stewardship interventions, self-
medication with over-the-counter antibiotics, and greater use of antibiotics for food production.32, 35 
Second, the clinical impact of each infection might be greater in LMICs because of barriers to health-care 
access, diagnostic testing, and therapeutic options.36 Finally, the molecular basis of carbapenem 
resistance varies by geographical region,37 so regional molecular data are required to evaluate the 
potential use of newer antimicrobial agents with activity against specific carbapenemase types. 
The findings of this study are consistent with, and extend, the existing literature regarding the health 
impact and microbiology of carbapenem resistance among Enterobacteriaceae causing bloodstream 
infection in LMICs.38, 39, 40, 41 Villegas and colleagues41 recruited patients from 11 hospitals in seven Latin 
American countries and found that CRE bloodstream infection was associated with a four-times increase 
in the odds of in-hospital mortality compared with CSE bloodstream infection.42 In this study, in-hospital 
mortality occurred in 35 (20%) of 174 patients with CSE bloodstream infection and in 43 (35%) of 123 
patients with CRE bloodstream infection. We caution against directly comparing this result with recent 
studies from high-income settings without considering other differences in patient cohorts, including 
time period, patient acuity, and antibiotic susceptibilities. The INCREMENT study,43 done in 26 tertiary 
hospitals in ten countries, reported 30-day all-cause mortality of 43% (189 of 437) in predominantly 
southern European patients with bloodstream infection due to carbapenemase-producing 
Enterobacteriaceae. The higher mortality than in our study might relate to changes in the management of 
carbapenemase-producing Enterobacteriaceae over time; 404 (92%) of 437 patients in the INCREMENT 
study had infections from 2004 to 2011, and mortality was significantly higher among those patients than 
among those with infections from 2012 to 2013 (adjusted hazard ratio 1·43, 95% CI 1·02–2·01). Although 
several other factors are likely to be relevant, this secular trend is supported by smaller studies in high-
income settings.6, 7, 44 Additionally, INCREMENT excluded patients who had received appropriate 
antibiotics before bloodstream infection onset and used a different outcome measure to that used in our 
study (30-day vs in-hospital mortality). 
The most common carbapenemase genes detected in this study were blaNDM and blaOXA-48-like, consistent 
with the large number of isolates from south Asia, which is the recognised epicentre of blaNDM and a 
region noted for more recent spread of OXA-48-like producing Enterobacteriaceae.45 As previously 
described, we found blaKPC in isolates from South America,45 but also in those from south Asia. No 
carbapenemase-encoding genes were identified in 13 CRE, suggesting the presence of other carbapenem 
resistance mechanisms. 
The most common K pneumoniae STs were ST14 and ST231. K pneumoniae ST14 is a non-virulent ST that 
has been associated with capsular serotype K2 and blaNDM,46, 47 a trend we also noted: eight of 15 K 
pneumoniae ST14 isolates from south Asia in this study carried blaNDM. Similarly, we found blaOXA-48-like 
genes in 12 of 14 K pneumoniae ST231 isolates (all from south Asia), as previously described.48 K 
pneumoniae ST258 is considered a high-risk international clone that is associated with clonal expansion of 
clades producing K pneumoniae carbapenemase.45 In this study, five K pneumoniae ST258 isolates 
carrying blaKPC genes were responsible for bloodstream infection cases in South America. 14 of 109 K 
pneumoniae isolates belonged to the clonal complex 258 (including ST258, ST11, ST340, and ST2516), 
which is associated with multidrug resistance and hospital dissemination.49 The most common E coli ST 
was ST131, a high-risk international clone associated with blaCTX-M-15.45 
A strength of this study is its prospective design, which facilitated accurate data collection. We also 
sought to provide valid estimates by explicitly accounting for competing outcomes and time-varying 
exposures. We did sensitivity analyses to explore the potential effect of misclassification of carbapenem 
susceptibility. To address the possibility of misclassification bias, we did all analyses on a subset of 
patients whose bacterial strains were characterised using phenotypic and molecular methods in one of 
two central study laboratories (ie, confirmed cohort). The multicentre nature of the study supports 
external validity. Finally, the molecular characterisation of dominant clades and carbapenemase genes 
adds detailed genetic information that is often lacking in clinical studies. 
We acknowledge that this study has limitations. First, by fixing an equal ratio of susceptible and resistant 
infections, we are unable to directly establish the incidence of our exposure. This concession was made to 
increase the efficiency of our study (ie, to produce more precise estimates for a given sample size). 
Second, we restricted this study to tertiary institutions in large metropolitan areas to minimise 
information bias, assure feasibility, and reduce heterogeneity, but this strategy limits the generalisability 
of our findings. In rural hospitals, the clinical effect might be even greater due to the absence of adequate 
diagnostic and therapeutic infrastructure. Third, there is a substantial degree of heterogeneity present in 
this study with regard to hospital resources, patients (neonates vs adults), bacterial pathogens (E coli and 
K pneumoniae), and resistance mechanisms. We did not power this study to do subgroup analyses 
stratified by these parameters. Finally, by comparing patients with bloodstream infection due to CSE with 
those with bloodstream infection due to CRE, we have estimated the effect of carbapenem resistance 
among patients with bloodstream infection. We are unable to estimate the effect of Enterobacteriaceae 
bloodstream infection (susceptible or resistant) in the absence of an uninfected group. 
This study contributes to an improved understanding of the scale of the emerging threat of carbapenem 
resistance in LMICs. We provide detailed clinical data and molecular characterisation of strains, including 
high-risk multidrug-resistant clones with few remaining therapeutic options. We have produced a robust 
estimate of the mortality and excess length of hospital stay attributable to carbapenem resistance. When 
combined with incidence data, this study will inform estimates of the global health and economic burden 
of carbapenem resistance. In the future, affordable surveillance mechanisms, interventions to prevent 
infection, and management strategies should be developed to reduce the burden of bloodstream 
infections caused by CRE in LMICs. 
 
 
 
  
RESEARCH IN CONTEXT 
Evidence before this study 
We were provided with the results of an unpublished systematic review done by Pezzani and 
colleagues commissioned by WHO on the clinical burden of multidrug-resistant bacteria, 
which included studies published before July 15, 2017. This included six studies reporting the 
effect of carbapenem resistance on mortality and length of hospital stay among patients with 
bloodstream infection caused by Enterobacteriaceae spp in low-income and middle-income 
countries (LMICs). We added one publication by searching the PubMed database for studies 
published from July 1, 2007, to Nov 6, 2017, assessing the clinical effect of carbapenem 
resistaŶĐe iŶ LMICs. We used the searĐh terŵs ͞CarďapeŶeŵs͟ AND ͞Drug ResistaŶĐe, 
BaĐterial͟ OR ͞ĐarďapeŶeŵ-resistaŶt͟ OR ͞ĐarďapeŶeŵase-produĐiŶg͟ OR ͞ĐarďapeŶeŵase͟ 
AND ͞EŶteroďaĐteriaĐeae͟ AND ͞BaĐtereŵia͟ OR ͞ďloodstreaŵ iŶfeĐtioŶ͟ AND ͞DeǀelopiŶg 
ĐouŶtries͟ OR ͞loǁ-iŶĐoŵe͟ OR ͞ŵiddle-iŶĐoŵe͟. Altogether, this approaĐh Ǉielded seǀeŶ 
publications: three were case series without a comparator group, three were single-centre 
studies (two in Taiwan and one in Brazil) with 75 participants or fewer, and one was a 
multicentre cohort study in seven Latin American countries. Although most studies reported 
higher mortality and increased length of hospital stay among patients with carbapenem-
resistant bloodstream infections, existing studies were underpowered and not able to 
account adequately for confounding and time-dependent bias. No published data were 
identified from low-income countries or from Africa, the Middle East, or south Asia. 
Added value of this study 
We add to previous evidence by including patients from a broader range of LMICs, and by 
using an analytical approach to account for the fact that discharge alive is a competing risk 
for in-hospital mortality and differences in follow-up between patients. We found that 
carbapenem resistance is associated with increased mortality and length of hospital stay 
among patients with bloodstream infections due to Enterobacteriaceae in LMICs. To our 
knowledge, these data represent the most detailed description to date of clinical and 
microbiological features of bloodstream infections due to carbapenem-resistant versus 
carbapenem-susceptible Enterobacteriaceae in LMICs. We also show the feasibility of studies 
to generate estimates of antimicrobial resistance in LMICs. 
Implications of all the available evidence 
The prevalence of resistance to third-generation cephalosporins among Enterobacteriaceae 
is unacceptably high, and carbapenems are increasingly being used to treat bloodstream 
infections. Carbapenem resistance is resulting in excess deaths and health expenditure in 
LMICs. In the absence of coordinated surveillance, this burden might go unrecognised, and 
appropriate interventions will be delayed. Although there is a need to improve surveillance of 
antimicrobial resistance in LMICs, this must be accompanied by strategies to limit the effect 
of resistance on patients with infections. Future research should develop affordable 
mechanisms for surveillance, evaluate the clinical effectiveness of interventions for infection 
prevention and antimicrobial stewardship, and optimise the management of bloodstream 
infections caused by carbapenem-resistant Enterobacteriaceae in LMICs. 
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Figure 1. Trial profile 
 
More than one isolate was available from some participants in the confirmed cohort. The complete cohort analysis included all 
patients. The confirmed cohort analysis included the subset of patients whose bloodstream infection strain was transported to 
a central study laboratory for confirmatory testing. CRE=carbapenem-resistant Enterobacteriaceae. CSE=carbapenem-
susceptible Enterobacteriaceae. 
 
  
Figure 2. Time from hospital admission to bloodstream infection and outcome,  
stratified by carbapenem susceptibility 
 
Each line represents one patient admission. Admissions are arranged vertically according to time from 
admission to bloodstream infection onset. Filled circles indicate bloodstream infection onset. Stars at 
the end of bars show mortality. CRE=carbapenem-resistant Enterobacteriaceae. CSE=carbapenem-
susceptible Enterobacteriaceae. 
 
  
Figure 3. eBURST diagrams of Klebsiella pneumoniae (A) and Escherichia coli (B) isolates showing the 
relationship between isolates on the basis of their multilocus sequence typing and carbapenem 
susceptibility 
 
Each node within the tree represents a single ST. The size of the nodes is proportional to the number of isolates represented 
by said node. Within each node, the area of blue and orange represents the number of carbapenem-susceptible and 
carbapenem-resistant strains. Nodes are labelled with corresponding ST. Nodes representing new STs are delineated with a 
green circle. ST=sequence type. CR=carbapenem-resistant. CS=carbapenem-susceptible. 
  
Table 1. Patient characteristics 
   CSE BSI (n=174) CRE BSI (n=123) 
 Demographics   
  Age (years) 46·0 (9·0–64·8) 46·0 (21·5–60·0) 
  Sex 
  Female 74 (43%) 41 (33%) 
  Male 100 (57%) 82 (67%) 
 Education among participants aged at least 18 years* 
   None 9 (8%) 13 (14%) 
   Primary 10 (8%) 10 (11%) 
   Secondary 28 (24%) 20 (21%) 
   Tertiary 42 (35%) 25 (36%) 
   Not available 30 (25%) 27 (28%) 
 Open defecation at home 
   Yes 14 (8%) 6 (5%) 
   No 139 (80%) 97 (79%) 
   Not available 21 (12%) 20 (16%) 
 Location before admission 
   Home 117 (67%) 62 (50%) 
   Transfer from other hospital 40 (23%) 48 (39%) 
   Long-term care 0 1 (1%) 
   Born this episode 14 (8%) 5 (4%) 
   Not available 3 (2%) 7 (6%) 
  Age-adjusted Charlson comorbidity index 2·0 (0·0–5·0) 2·0 (0·0–4·5) 
   Health-care exposures before BSI onset   
   Antibiotic exposure (within 30 days)   
   Yes 76 (44%) 70 (57%) 
   No 80 (46%) 34 (28%) 
   Not available 18 (10%) 19 (15%) 
 ICU admission (within 30 days) 
   Yes 51 (29%) 54 (44%) 
   No 123 (71%) 69 (56%) 
 Surgery (within 30 days) 
   Yes 26 (15%) 27 (22%) 
   No 148 (85%) 96 (78%) 
 Immunosuppressive therapy (within 3 months) 
  Yes 27 (16%) 18 (15%) 
  No 143 (82%) 103 (84%) 
  Not available 4 (2%) 2 (2%) 
 Previous hospitalisation (within 12 months) 
   CSE BSI (n=174) CRE BSI (n=123) 
  Yes 96 (55%) 77 (63%) 
  No 77 (44%) 46 (37%) 
  Not available 1 (1%) 0 (0%) 
 Qualifying Enterobacteriaceae 
   Escherichia coli 83 (48%) 20 (16%) 
   Klebsiella species 69 (40%) 85 (69%) 
   Other Enterobacteriaceae 19 (11%) 10 (8%) 
   More than one Enterobacteriaceae 3 (2%) 8 (7%) 
  ICU at time of BSI onset 73 (42%) 68 (55%) 
  Pitt bacteraemia score at BSI onsetΏ 2·0 (0·0–4·0) 2·5 (1·0–5·0) 
 Epidemiological classification   
  Community acquired 60 (34%) 11 (9%) 
  Hospital acquired 69 (40%) 65 (53%) 
  Health-care associated with community onset 25 (14%) 29 (24%) 
  Not available 20 (11%) 18 (15%) 
 Source   
 Primary 99 (57%) 59 (48%) 
 Central-line associated 18 (10%) 26 (21%) 
 Secondaryΐ 57 (33%) 38 (31%) 
   CNS 1 (2%) 2 (5%) 
  Cardiovascular system infection 0 1 (3%) 
  Gastrointestinal system infection 14 (25%) 8 (21%) 
  Lower respiratory infection, other than pneumoni 6 (11%) 3 (8%) 
  Pneumonia or ventilator-associated event 12 (21%) 6 (16%) 
  Reproductive tract infection 1 (2%) 0 
  Surgical site infection 3 (5%) 4 (11%) 
  Skin and soft tissue infection 0 9 (24%) 
 Urinary tract infection 20 (35%) 5 (13%) 
 Total length of stay (days) 11·0 (6·0–24·0) 19·0 (10·0–31·5) 
 
Data are n (%) or median (IQR). CSE=carbapenem-susceptible Enterobacteriaceae. BSI=bloodstream infection. 
CRE=carbapenem-resistant Enterobacteriaceae. ICU=intensive care unit. 
•   119 patients with CSE BSI and 95 patients with CRE BSI were aged at least 18 years. 
Ώ   Not available for one patient with CSE BSI and one patient with CRE BSI. 
ΐ  For sources of secondary BSI, percentages represent the proportion of all secondary BSIs accounted for by that   
     source (stratified by carbapenem susceptibility). 
  
 Table 2. Effect of carbapenem resistance on in-hospital death and discharge alive  
from proportional subdistribution hazards models* 
 Subdistribution  
HR (95% CI) 
In-hospital mortality 
Base analysis 1·68 (1·07–2·64) 
Inverse probability weighted analysis 1·75 (1·04–2·94) 
Alive at discharge 
Base analysis 0·63 (0·48–0·84) 
Inverse probability weighted analysis 0·61 (0·45–0·83) 
  HR=hazard ratio. 
*    Analysis done on the complete cohort; all models include time from admission to infection as a covariate 
. 
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